On December 13, 2023, the National Health Insurance Administration announced the results of the adjustment of the National Medical Insurance Drug List for the new year. This year, a total of 143 drugs outside the catalogue participated in the negotiation or bidding, of which 121 drugs successfully entered the catalogue, with a negotiation success rate of 846%, with an average price reduction of 617%, which is basically the same as in 2022.
A total of 126 drugs have been added to the new medical insurance list, while only 1 drug has been removed. After the adjustment, the total number of drugs in the medical insurance drug catalogue reached 3,088, including 1,698 western medicines and 1,390 Chinese patent medicines, and the types of traditional Chinese medicine decoction pieces remained unchanged at 892.
The new version of the medical insurance catalogue will be officially implemented from January 1, 2024. From the public's point of view, a price reduction of more than 60% will further reduce the burden of medication on patients. From the perspective of enterprises, how to support drug innovation and sustainable development of enterprises through medical insurance payment methods has been a hot topic recently.
At the press conference, the relevant person in charge of the National Health Insurance Administration emphasized the measures and data to support innovation, pointing out that in 2023, 25 innovative drugs will participate in the negotiation of the medical insurance catalog, of which 23 will be successful, with a success rate of 92%, which is 7 higher than the overall average success rate4%, with an average decrease of 44%。
Some multinational pharmaceutical companies such as Biogen, Novartis, AstraZeneca, etc., have also quickly announced the latest inclusion of their products in the medical insurance list. In the domestic market, the ** of some pharmaceutical companies have had mixed reactions to entering the medical insurance catalog, but on the whole, the market has not had significant fluctuations in this news.
Star varieties that have attracted much attention, such as two CAR-T** and two GLP-1 drugs, two of which have not been included in the medical insurance catalogue due to their high **. Semaglutide, a GLP-1 drug, was included in the medical insurance because it was used for type 2 diabetes, but its high-profile ** indications were not included in the medical insurance.